Note: results can be filtered by year and/or keyword. To filter on year, select the appropriate year from the drop down menu. To filter on keyword, enter relevant term into open box, select appropriate keyword, and click "filter".
Statements, Speeches, Letters
Médecins Sans Frontières (MSF), ACTION Global Health Advocacy Partnership, SWIFT Response Project, Treatment Action Campaign (TAC), Treatment Action Group (TAG) and others are calling on global health actors to step up and ensure new and repurposed DR-TB drugs reach people who are otherwise without treatment options. SIGN ON LETTER to global actors and drug companies
Last updated 10 March 2015
MSF Access Campaign made a submission to IP (Intellectual Property) Think Tank committee set up by Ministry of Commerce in India on the draft IP policy released for public comments. While the draft policy touches on many aspects of Intellectual Property, MSF has provided comments specifically on the following six areas concerning IP, innovation and access to medicines: I. Perspective on IP, innovation and access to medicines
Last updated 3 March 2015
Ahead of the 1st Eastern Partnership Ministerial Conference on Tuberculosis (TB) and Multidrug Resistant Tuberculosis due to be held in Riga on 30-31 March, we share our experience and recommedations on how to address the deadly gaps in fighting TB.
Last updated 19 February 2015
136th WHO Executive Board Agenda item 10.5 Global strategy and plan of action on public health, innovation and intellectual property Speaker: Katy Athersuch, Medical Access and Innovation Policy Advisor
Last updated 30 January 2015
136th WHO Executive Board Agenda item 10.4 Follow-up of the report of the Consultative Expert Working Group on Research and Development: Financing and Coordination Speaker: Katy Athersuch, Medical Access and Innovation Policy Advisor Médecins Sans Frontières is concerned by the lack of action by WHO and Member States in the face of clear and urgent recommendations in the CEWG report to address the collective under-investment in research and development to meet developing country health needs.
Last updated 30 January 2015
136th WHO Executive Board Agenda item 8.1 Antimicrobial resistanceSpeaker: Dr Arlene Chua, Antimicrobial Resistance Advisor
Last updated 29 January 2015
136th WHO Executive Board Agenda item 9.3 Global Vaccine Action PlanSpeaker: Nathalie Ernoult, Head of Advocacy, Regional and Francophone Médecins Sans Frontières welcomes the recommendations of the Strategic Advisory Group of Experts on the Global Vaccine Action Plan report. During the sixty-seventh World Health Assembly, over thirty Member States expressed concern over the high price of new vaccines, calling for WHO to develop strategies to increase affordability.
Last updated 27 January 2015
Médecins Sans Frontières/Doctors Without Borders (MSF) and other organisations are demanding that the US government reconsider some of the provisions of the Trans-Pacific Partnership (TPP) that threaten the production and distribution of generic medicines in signatory countries. Without generic medicines the price of lifesaving drugs and treatments would be maintained at prices many people in the developing world are unable to afford. The more expensive these drugs are, the less people we can treat.
Last updated 16 December 2014
New York, December 8, 2014 President Barack Obama The White House 1600 Pennsylvania Avenue NW Washington, DC 20500 Dear Mr. President: We are writing on behalf of Médecins Sans Frontières/Doctors Without Borders (MSF) to express our deep concern over provisions under negotiation in the Trans-Pacific Partnership Agreement (TPP) that threaten to restrict access to affordable medicines and much-needed innovation for millions of people, and for treatment providers like MSF and Ministries of Health.
Last updated 8 December 2014
The European Union is currently negotiating new rules on European trademarks and are proposing language which will increase the risk of generic lifesaving medicines being stopped, seized and even destroyed while they are in transit in Europe en route to people in developing countries.
Last updated 3 December 2014